Elon Musk’s Neuralink is shifting into high gear for 2026 as the company’s co-founder touts changes to the brain-computer ...

Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...

Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the ...

Koroshetz’s exit—expected Jan. 24—means that 14 of the NIH’s 27 units will be helmed by interim leaders. NINDS acting deputy ...

AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a new clinical-stage cancer drug. | ...

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

After five years, Nido Biosciences has reached the end of the road, closing its doors after its lead neurological disease ...

Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of ...

Pieper is now working to advance P7C3-A20 through Glengary Brain Health, a Cleveland-based company that he cofounded, according to the release. Pieper’s team had previously found that the ...

Alzheimer’s disease blood test developer Quanterix put forward new clinical data from its Simoa assay, which it described as ...

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the ...